For the roughly 6 million people worldwide living with Down syndrome, the immune system has long been understood as compromised — but the molecular reasons remained fragmented. A comprehensive review in the Journal of Clinical Immunology now synthesizes the mechanistic picture with striking clarity, reframing Down syndrome not merely as a developmental condition but as a state of chronic, genetically programmed immune dysfunction with direct consequences for infection risk and vaccine strategy.
The central mechanism is rooted in gene dosage. Chromosome 21 carries genes encoding interferon receptors, and having three copies drives persistent hyperactivation of type I interferon signaling, sustaining JAK-STAT pathway activity and constitutive expression of interferon-stimulated genes. This creates a paradoxical state: immune cells are chronically stimulated yet functionally impaired. Specific deficits catalogued include blunted neutrophil chemotaxis, polarization of monocytes toward pro-inflammatory phenotypes, contraction of naïve T- and B-cell pools, narrowed antigen receptor diversity, and depleted class-switched memory B cells — collectively resembling accelerated immunosenescence. In clinical terms, cohort data show heightened hospitalization and mortality from RSV, influenza, and SARS-CoV-2, alongside lower peak antibody titers and faster waning post-vaccination.
This synthesis carries meaningful implications beyond the Down syndrome population itself. The interferon hyperactivation profile observed here echoes mechanisms seen in aging-associated inflammaging and in certain autoimmune conditions, suggesting that Down syndrome may serve as a tractable human model for studying chronic innate immune dysregulation. From a translational standpoint, JAK inhibitors already approved for inflammatory diseases represent a plausible intervention avenue, though no clinical trial data yet exist for this indication. The review is observational and integrative rather than experimental, so causality for specific clinical outcomes remains inferred. Nonetheless, the mechanistic framework it establishes is unusually coherent for this population and should prompt reconsideration of standard vaccination schedules and booster intervals for individuals with trisomy 21.